| 货号 | 16316-1mg |
| 描述 | Peripherally-restricted cannabinoid receptor 1 (CB1) selective antagonists have the potential to inhibit food intake while also escaping centrally-mediated neuropsychiatric side effects. AM6545 is a novel CB1 selective neutral antagonist with low CNS penetration, exhibiting Ki values of 1.7 and 523 nM for CB1 and CB2 receptors, respectively.1 It reduces food intake and food-reinforced behavior, such as time spent feeding, in a dose-dependent manner, resulting in decreased body weight.1,2 AM6545 produces improvements in glucose homeostasis, fatty liver, and plasma lipid profiles in mice with diet-induced obesity.3 It does not affect behavior responses that are associated with activation of CB1 receptors in the brain.3 |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Cluny, N.L.,Vemuri, V.K.,Chambers, A.P., et al. A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents. British Journal of Pharmacology 161(3), 629-642 (2010). 2.Randall, P.A.,Vemuri, V.K.,Segovia, K.N., et al. The novel cannabinoid CB1 antagonist AM6545 suppresses food intake and food-reinforced behavior. Pharmacology, Biochemistry, and Behavior 97(1), 179-184 (2010). 3.Tam, J.,Vemuri, V.K.,Liu, J., et al. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. Journal of Clinical Investigation 120(8), 2953-2966 (2010). | |
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 556.5 |
| 分子式 | C26H23Cl2N5O3S |
| CAS号 | 1245626-05-4 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |